Gadolinium-primarily based distinction brokers (GBCAs) are broadly used in magnetic resonance imaging (MRI) to improve the visibility of blood vessels, tumors, inflammation, and other inside structures. Though frequently viewed as Protected, concerns about GBCA toxicity have emerged in the last twenty years—specially in individuals with impaired